Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matter?
- 17 Downloads
Increasingly, government policies directed towards limiting pharmaceutical prices have emphasized value-based criteria. This regulatory approach is most clearly formalized in the United Kingdom where the National Institute for Health and Clinical Excellence (NICE) was created within the British National Health Service (NHS), whose function is to apply cost-effectiveness analysis to new drugs. In contrast to Britain, there is no formal regulatory mechanism assuring cost-effectiveness in the United States. Instead, questions of cost effectiveness are left to market processes. In this paper, we examine the pricing implications of these alternate regimes. From our empirical analysis, we conclude that value-based pricing is enforced by both regulatory and market processes, and with similar outcomes.
KeywordsDrug prices Value-based pricing Cost-effectiviness analysis
- Department of Health and the Association of the British Pharmaceutical Industry. (2013). The pharmaceutical price regulation scheme 2014, December 2013, Gov.UK.Google Scholar
- Drummond, M., et al. (1987). Methods for economic evaluation of health care programmes. New York: Oxford University Press.Google Scholar
- George, E. (2010). Associate Director of NICE, Interview, London, April 2010.Google Scholar
- Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost effectiveness in health and medicine. New York: Oxford University Press.Google Scholar
- IMS Institute for Healthcare Informatics. (2015). Medicines use and spending shifts. Parsippany, NJ.Google Scholar
- Nolte, E., & Corbett, J. (2014). International variation in drug usage. London: RAND Europe.Google Scholar
- O’Neill, P., & Sussex, J. (2014). International comparison of medicines usage: Quantitative analysis. London: Office of Health Economics.Google Scholar
- Richards, M. (2010). Extent and causes of international variations in drug use. A report for the Secretary of State for Health, UK, July 2010.Google Scholar
- Scherer, F. M. (2000). The pharmaceutical industry. In A. J. Culyer & J. P. Newhouse (Eds.), Handbook of health economics (pp. 1298–1336). Amsterdam: Elsevier.Google Scholar
- Schweitzer, S. O. (2007). Pharmaceutical economics and policy (2nd ed.). New York: Oxford University Press.Google Scholar
- US Center for Health Statistics. (2014). Health United States. Washington: Department of Health and Human Services.Google Scholar